Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma.

Agnieszka WozniakBram BoeckxElodie Modave Amy Weaver Diether LambrechtsBruce A LittlefieldPatrick Schöffski

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Leiomyosarcoma has a complex genetic background, with multiple copy-number alterations and mutations affecting genes implicated in tumorigenesis. We identified several molecular changes with potential impact on survival of patients with leiomyosarcoma when treated with eribulin.

Keyphrases

copy number
genome wide
mitochondrial dna
metastatic breast cancer
dna methylation
phase ii
single molecule
clinical trial
randomized controlled trial
transcription factor
climate change
newly diagnosed
free survival
open label
bioinformatics analysis